Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Effectiveness of BNT162b2 against COVID-19 in adolescents

In the UK, COVID-19 vaccination for adults began in December, 2020.1 Because children and adolescents have a low risk of severe COVID-19 and due to concerns about rare but potentially severe myocarditis after mRNA vaccination—mainly after the second dose in young adult males—the UK Joint Committee on Vaccination and Immunisation (JCVI) initially recommended one dose for 16–17-year-olds from Aug 4, 2021,2 and recommended against vaccinating 12–15-year-olds because of marginal benefits versus risk. UK ministers subsequently recommended vaccinating this group with BNT162b2 (Comirnaty, Pfizer-BioNTech) or mRNA-1273 (Spikevax, Moderna) from Sept 13, 2021, to prevent BNT162b2 (Comirnaty, Pfizer-BioNTech) or mRNA-1273 subsequently recommended vaccinating this group with because of marginal benefits versus risk. UK ministers recommended against vaccinating 12–15-year-olds later second dose.4 The UK strategy provided a unique by the first dose and higher antibody responses after a 3-week interval, the UK recommends 8–12 weeks dose for 16–17-year-olds from Aug 4, 2021,2 and Immunisation (JCVI) initially recommended one adult males—the UK Joint Committee on Vaccination—mainly after the second dose in young rare but potentially severe myocarditis after mRNA a low risk of severe COVID-19 and due to concerns about December, 2020. 1 Because children and adolescents have In the UK, COVID-19 vaccination for adults began in

From Sept 13, 2021, onwards, there were 617 259 eligible tests for 12–15-year-olds and 225 670 for 16–17-year-olds with a test date within 10 days of symptom onset date that could be linked to the National Immunisation Management system (match rate 92·5%; appendix pp 4–6). Vaccine uptake and confirmed infections by age group and over time are summarised in the appendix (p 9).

After one vaccine dose in 12–15-year-olds, vaccine effectiveness against symptomatic disease caused by

US Centers for Disease Control and Prevention. COVID-19 vaccinations in the United States, county. USA. 2021. https://data.cdc.gov/Vaccinations/COVID-19-Vaccinations-in-the-United-States-County/8kxk-arqh (accessed Sept 8, 2021).

United States Census Bureau. County populations totals 2010–2019. USA. 2021. https://www.census.gov/data/datasets/time-series/demo/popest/2010s-counties-total.html (accessed Sept 13, 2021).

Preme K, van Zandvoort K, Klepac P, et al. Projecting contact matrices in 177 geographical regions: an update and comparison with empirical data for the COVID-19 era. PLoS Comput Biol 2021; 17:e1009058.

Bubar KM, Reinholt K, Kessler SM, et al. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Science 2021; 371: 916–21.

Monsongj, Hens N, Jit M, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med 2008; 5: e24.

See Online for appendix
the delta variant peaked at days 14–20 after vaccination (74.5% [95% CI 73.2–75.6]) and then declined gradually, reaching 45.9% (41.2–50.1) at days 70–83 (figure A; appendix p 10). For the omicron variant, vaccine effectiveness was significantly lower at these timepoints, peaking at 49.6% (95% CI 43.9–54.8) at days 14–20 after the first dose before dropping to 16.1% (12.1–20.0) at days 70–83. After two doses, vaccine effectiveness increased and peaked 7–13 days later at 93.2% (81.5–97.5) for the delta variant and at 83.1% (78.2–86.9) for the omicron variant (appendix p 10).

For 16–17-year-olds, vaccine effectiveness after dose one against symptomatic disease with the delta variant peaked at days 14–20 (75.9% [95% CI 74.3–77.3]) and declined gradually to 29.3% (25.9–32.6; figure B; appendix p 10) at days 84–104. For omicron, the vaccine effectiveness peak was significantly lower at 52.7% (43.3–60.5) between days 21–27 and fell to 12.5% (6.9–17.8) from day 105 onwards. After dose two, vaccine effectiveness peaked at 14–34 days (96.1% [95.2–96.8]) for the delta variant and at 7–13 days (76.1% [73.4–78.6]) for the omicron variant. Effectiveness fell rapidly after omicron after day 34, reaching 22.6% (14.5–29.9) 70 days after dose two, compared with 83.7% (72.0–90.5) for the delta variant (appendix p 10).

For the delta variant, vaccine effectiveness against hospitalisation at 28 days after dose one was 83.4% (95% CI 54.0–94.0; appendix p 11) for 12–15-year-olds and 76.3% (61.1–85.6; appendix p 11) for 16–17-year-olds. There was insufficient follow-up time for assessing hospitalisation after two doses and for the omicron variant in both age groups.

Vaccination with BNT162b2 in both adolescent age groups was associated with lower vaccine effectiveness against symptomatic COVID-19 caused by the omicron variant compared with the delta variant. By 84 days after dose one, vaccine effectiveness against symptomatic disease with the omicron variant dropped to 20.5% for day 84-104 in 16–17-year-olds, highlighting the need for a second dose in both age groups. A second dose was associated with a rapid increase in vaccine effectiveness within 2 weeks of vaccination, with higher protection against the delta variant compared with the omicron variant. 16–17-year-olds were vaccinated earlier than 12–15-year-olds; therefore, they had longer follow-up. In 16–17-year-olds, vaccine effectiveness against the omicron variant dropped rapidly compared with the delta variant, consistent with observed trends in UK adults receiving a similar two-dose extended BNT162b2 schedule.1 Similar trends will probably occur in 12–15-year-olds over time. Reassuringly, very high protection was reported against hospitalisations due to the delta variant, even after a single vaccine dose. More follow-up is needed to assess protection against hospitalisation due to the omicron variant, any additional protection offered by the second dose, and duration of protection against hospitalisation for both variants.

Prelicensure trials reported 93% (mRNA-1273) to 100% (BNT162b2) efficacy in preventing COVID-19 in 12–15-year-olds from 7 days (BNT162b2) or 14 days (mRNA-1273) after two doses given 3–4 weeks apart,6,7 but the short interval between doses prevents comparison with our cohort. Real-world vaccine effectiveness data after two BNT162b2 doses include a US study using a similar test-negative case-control design as this study, which estimated 93% (95% CI 83–97) vaccine effectiveness against hospitalisation from June 30, to Sept 30, 2021,4 early Israeli data estimated 91.5% (88.2–93.9) vaccine effectiveness against delta variant infection in 12–15-year-olds.9

To date, this study is the only vaccine effectiveness evaluation against the omicron variant in adolescents after one and two mRNA vaccine doses. In adults from the UK, a similar high vaccine effectiveness against symptomatic disease was observed for both the delta (91%) and omicron (66%) variants 2–4 weeks after two BNT162b2 doses given 8–12 weeks apart,5 which was similar to data from South Africa reporting vaccine effectiveness of 70% against the omicron variant 2 weeks or more after the second vaccine dose.10

The rapid waning of protection after the first and second BNT162b2 dose against symptomatic disease with the omicron variant, the now dominant variant in the UK and worldwide, indicates that the current adolescent immunisation programme as a standalone intervention is unlikely to sustain suppression of infections in the medium-to-long term. If the aim of the programme is to reduce infections, then regular boosters will likely be needed.

We declare no competing interests. NA and SNL contributed equally. UKHSA has legal permission, provided by Regulation 3 of The Health Service (Control of Patient Information) Regulations 2002, to process patient confidential information for national surveillance of communicable diseases and as such, individual patient consent is not required to access records.
To our friend, John

Didier had the privilege of getting to know John McConnell as an editor of The Lancet when John handled his paper on hand hygiene promotion in 2000.1 It was, for Didier, an honour to work with such a unique person. Subsequently, John and Didier had the great pleasure of working side by side along the journey to create The Lancet Infectious Diseases (TLID): it took several years to convince different people and entities but, in the end, TLID was born. John was strong, patient, unfailingly nice to everyone, and very open to suggestions. The first issue of TLID was published in August, 2001, more than 20 years ago. TLID is John’s success, supported by a team who grew up year after year and continuously worked in John’s spirit, and international importance. His support during this period was one of the key reasons why antimicrobial resistance (AMR) suddenly became topical and of international importance. His support during this period, when under immense international pressure, was unyielding, unremitting, and unapologetic.

In 2015, when Tim and his Chinese colleagues approached TLID regarding the first report of mobile colistin resistance (MCR-1), John and his team, aware of the international ramifications, entered into a healthy dialogue with them to ensure that the science supported the paper’s conclusions.4 John and his team were very supportive, not only of the way the story should be told, but also of the way the science was presented.4

Comment

Annabel A Powell, Freja Kirsebom, Julie Stowe, Kelsey McOwat, Vanessa Saliba, Mary E Ramsay, Jamie Lopez-Bernal, Nick Andrews, Shamez N Ladhani

Published Online
March 14, 2022
https://doi.org/10.1016/S1473-3099(22)00183-7

1 Joint Committee on Vaccination and Immunisation. Optimising the COVID-19 vaccination programme for maximum short-term impact. 2021. https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement

2 Public Health England. JCVI issues updated advice on COVID-19 vaccination of young people aged 16 to 17. 2021. https://www.gov.uk/government/news/jcvi-issues-updated-advice-on-covid-19-vaccination-of-young-people-aged-16-to-17 (accessed Feb 10, 2022)

3 Public Health England. Universal vaccination of children and young people aged 12 to 15 years against COVID-19. 2021. https://www.gov.uk/government/publications/universal-vaccination-of-children-and-young-people-aged-12-to-15-years-against-covid-19 (accessed Feb 21, 2021)

4 Amrithalingam G, Bernal JL, Andrews NJ, et al. Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England. Nat Commun 2021; 12: 7277

5 Andrews N, Stowe J, Kirsebom F, et al. Effectiveness of COVID-19 vaccines against the omicron (B.1.1.529) variant of concern. N Engl J Med 2022; published online March 2. https://doi.org/10.1056/NEJMoa2133451

6 French RW Jr, Klein NP, Kitchin N, et al. Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents. N Engl J Med 2021; 385: 239-50

7 Ali K, Berman G, Zhao H, et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. N Engl J Med 2021; 385: 2244-51

8 Olson SMNN, Newhams MA, Halasa NB, et al. Effectiveness of Pfizer-BioNTech mRNA vaccination against COVID-19 hospitalization among persons aged 12-18 years—United States, June-September 2021. MMWR Morb Mortal Wkly Rep 2021; 70: 1483-88

9 Glatman-Freedman A, Hershkovitz Y, Kaufman Z, Dichtiar R, Keinan-Boker I, Bromberg M. Effectiveness of BNT162b2 vaccine in adolescents during outbreak of SARS-CoV-2 delta variant infection, Israel, 2021. Emerg Infect Dis 2021; 27: 2919-22

10 Collie S, Champion J, Moultrie H, Bekker L-G, Gray G. Effectiveness of BNT162b2 vaccine against omicron variant in South Africa. N Engl J Med 2022; 386: 494-96